Diagnostic Value of Immunohistochemical Markers in Four-grade Histological Classification of Hepatocellular Carcinoma

Feiqian Wang(First Affiliated Hospital of Xi'an Jiaotong University), Shin Maeda(University of Tokyo Hospital), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Masahiro Okada, Masako Otani(Mita Hospital), Akito Nozaki(Yokohama City University Medical Center), Hiromi Nihonmatsu(Yokohama City University Medical Center), Mikiko Tanabe(Yokohama City University Medical Center), Litao Ruan(First Affiliated Hospital of Xi'an Jiaotong University), Masayuki Nakano(Nihon University), Yoshiaki Inayama(Yokohama City University Medical Center), Wen Luo(Xijing Hospital), Satoshi Moriya(Yokohama City University Medical Center)
Unknown
November 2, 2020
10.21203/rs.3.rs-99711/v1
Cited by 2

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283